A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

Trial Profile

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DANUBE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to active, no longer recruiting, according to a Biologics Inc media release.
    • 22 May 2017 According to a Biologics Inc media release, last patient has commenced dosing during the first quarter of 2017.
    • 15 Feb 2017 Planned primary completion date changed from 1 Mar 2018 to 2 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top